Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16433685 | 0.82 | MAPT (0.34) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL10103766 | 0.80 | RAB9A (0.36) | SMN1; SMN2NPC1HTTRAB9AMAPT | |
| SCHEMBL21324892 | 0.79 | NPC1 (0.45) | SMN1; SMN2NPC1HTTRAB9A | |
| SCHEMBL10116209 | 0.79 | MAPT (0.39) | SMN1; SMN2NPC1HTTRAB9AMAPT | |
| SCHEMBL12933349 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2NPC1HTTRAB9AMAPT | |
| SCHEMBL18066924 | 0.76 | GBA1 (0.32) | SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL10103780 | 0.72 | CHRM2 (0.33) | SMN1; SMN2NPC1HTTRAB9AMAPT | |
| SCHEMBL10103756 | 0.72 | NPC1 (0.42) | SMN1; SMN2NPC1HTTRAB9A | |
| SCHEMBL20134460 | 0.71 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1HTTRAB9AMAPT | |
| SCHEMBL13332910 | 0.71 | KDM4E (0.35) | SMN1; SMN2NPC1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946231-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2010111059-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | SMN1; SMN2 1758/4885NPC1 3891/4885HTT 3196/4885 |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | SMN1; SMN2 2075/4885NPC1 4049/4885HTT 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.